Start with a free account for 12 free CME credits. Already a subscriber? Sign in.
Chapter 2

New IDSA Pneumonia Guidelines

Rob Orman, MD and Clay Smith, MD
00:00
31:20
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

Clay Smith is back to break down the high (and possibly low) points of the new pneumonia guidelines.

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

Ross B. -

My understanding was that the evidence regarding Tamiflu affecting patient outcomes and complications was pretty limited and conflicting. Could you discuss this data more in depth? It’s hard to recommend a medication to a patient for a disease when it’s expensive, has limited efficacy, and has side effects (and it’s surprising that the guidelines suggest we give it despite duration of illness...). I guess I’m pretty skeptical of pharma-sponsored trials...

Rob O., MD -

Hey Ross! The evidence for oseltamivir is wrapped in conflict of interest, shrouded in bias, and nauseatingly presented by those who appear to be in the pocket of the drug manufacturer.

Here is a look at the evidence I did a few years back on another podcast (might answer some of your questions, though won't alleviate your concerns)
https://podtail.com/podcast/questioning-medicine/44-robbing-the-evidence-around-tamiflu/

Let me know if this helps. If not, we'll go even deeper.
Keep on rocking,
Rob O

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To earn CME for this chapter, you need to subscribe.

Sign up today for full access to all episodes and earn CME.

2.25 AMA PRA Category 1 Credits™ certified by Hippo Education (2020)